These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 27786353)
1. Longitudinal study of cerebral surface morphology in youth with 22q11.2 deletion syndrome, and association with positive symptoms of psychosis. Radoeva PD; Bansal R; Antshel KM; Fremont W; Peterson BS; Kates WR J Child Psychol Psychiatry; 2017 Mar; 58(3):305-314. PubMed ID: 27786353 [TBL] [Abstract][Full Text] [Related]
2. Longitudinal trajectories of cortical thickness as a biomarker for psychosis in individuals with 22q11.2 deletion syndrome. Ramanathan S; Mattiaccio LM; Coman IL; Botti JC; Fremont W; Faraone SV; Antshel KM; Kates WR Schizophr Res; 2017 Oct; 188():35-41. PubMed ID: 27988073 [TBL] [Abstract][Full Text] [Related]
3. Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. Bakker G; Caan MW; Vingerhoets WA; da Silva-Alves F; de Koning M; Boot E; Nieman DH; de Haan L; Bloemen OJ; Booij J; van Amelsvoort TA PLoS One; 2016; 11(11):e0159928. PubMed ID: 27828960 [TBL] [Abstract][Full Text] [Related]
4. Deviant trajectories of cortical maturation in 22q11.2 deletion syndrome (22q11DS): a cross-sectional and longitudinal study. Schaer M; Debbané M; Bach Cuadra M; Ottet MC; Glaser B; Thiran JP; Eliez S Schizophr Res; 2009 Dec; 115(2-3):182-90. PubMed ID: 19836927 [TBL] [Abstract][Full Text] [Related]
5. Trajectories of psychiatric diagnoses and medication usage in youth with 22q11.2 deletion syndrome: a 9-year longitudinal study. Kates WR; Mariano MA; Antshel KM; Chandra S; Gamble H; Giordano M; MacMaster E; Mattar M; St Fleur D; Faraone SV; Fremont WP Psychol Med; 2019 Aug; 49(11):1914-1922. PubMed ID: 30226117 [TBL] [Abstract][Full Text] [Related]
6. Cortical morphology development in patients with 22q11.2 deletion syndrome at ultra-high risk of psychosis. Padula MC; Schaer M; Armando M; Sandini C; Zöller D; Scariati E; Schneider M; Eliez S Psychol Med; 2018 Oct; 48(14):2375-2383. PubMed ID: 29338796 [TBL] [Abstract][Full Text] [Related]
7. Cortical-amygdala volumetric ratios predict onset of symptoms of psychosis in 22q11.2 deletion syndrome. Berhanu D; Mattiaccio LM; Antshel KM; Fremont W; Middleton FA; Kates WR Psychiatry Res Neuroimaging; 2017 Jan; 259():10-15. PubMed ID: 27918911 [TBL] [Abstract][Full Text] [Related]
8. Longitudinal study of premorbid adjustment in 22q11.2 deletion (velocardiofacial) syndrome and association with psychosis. Radoeva PD; Fremont W; Antshel KM; Kates WR Dev Psychopathol; 2017 Feb; 29(1):93-106. PubMed ID: 26864886 [TBL] [Abstract][Full Text] [Related]
9. Predicting Cognition and Psychosis in Young Adults With 22q11.2 Deletion Syndrome. Antshel KM; Fremont W; Ramanathan S; Kates WR Schizophr Bull; 2017 Jul; 43(4):833-842. PubMed ID: 27798222 [TBL] [Abstract][Full Text] [Related]
11. Aberrant Cortical Morphometry in the 22q11.2 Deletion Syndrome. Schmitt JE; Vandekar S; Yi J; Calkins ME; Ruparel K; Roalf DR; Whinna D; Souders MC; Satterwaite TD; Prabhakaran K; McDonald-McGinn DM; Zackai EH; Gur RC; Emanuel BS; Gur RE Biol Psychiatry; 2015 Jul; 78(2):135-43. PubMed ID: 25555483 [TBL] [Abstract][Full Text] [Related]
12. Positive psychotic symptoms are associated with divergent developmental trajectories of hippocampal volume during late adolescence in patients with 22q11DS. Mancini V; Sandini C; Padula MC; Zöller D; Schneider M; Schaer M; Eliez S Mol Psychiatry; 2020 Nov; 25(11):2844-2859. PubMed ID: 31164700 [TBL] [Abstract][Full Text] [Related]
13. Altered cortical thickness development in 22q11.2 deletion syndrome and association with psychotic symptoms. Bagautdinova J; Zöller D; Schaer M; Padula MC; Mancini V; Schneider M; Eliez S Mol Psychiatry; 2021 Dec; 26(12):7671-7678. PubMed ID: 34253864 [TBL] [Abstract][Full Text] [Related]
14. Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. Sun D; Ching CRK; Lin A; Forsyth JK; Kushan L; Vajdi A; Jalbrzikowski M; Hansen L; Villalon-Reina JE; Qu X; Jonas RK; van Amelsvoort T; Bakker G; Kates WR; Antshel KM; Fremont W; Campbell LE; McCabe KL; Daly E; Gudbrandsen M; Murphy CM; Murphy D; Craig M; Vorstman J; Fiksinski A; Koops S; Ruparel K; Roalf DR; Gur RE; Schmitt JE; Simon TJ; Goodrich-Hunsaker NJ; Durdle CA; Bassett AS; Chow EWC; Butcher NJ; Vila-Rodriguez F; Doherty J; Cunningham A; van den Bree MBM; Linden DEJ; Moss H; Owen MJ; Murphy KC; McDonald-McGinn DM; Emanuel B; van Erp TGM; Turner JA; Thompson PM; Bearden CE Mol Psychiatry; 2020 Aug; 25(8):1822-1834. PubMed ID: 29895892 [TBL] [Abstract][Full Text] [Related]
15. Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness. Ching CRK; Gutman BA; Sun D; Villalon Reina J; Ragothaman A; Isaev D; Zavaliangos-Petropulu A; Lin A; Jonas RK; Kushan L; Pacheco-Hansen L; Vajdi A; Forsyth JK; Jalbrzikowski M; Bakker G; van Amelsvoort T; Antshel KM; Fremont W; Kates WR; Campbell LE; McCabe KL; Craig MC; Daly E; Gudbrandsen M; Murphy CM; Murphy DG; Murphy KC; Fiksinski A; Koops S; Vorstman J; Crowley TB; Emanuel BS; Gur RE; McDonald-McGinn DM; Roalf DR; Ruparel K; Schmitt JE; Zackai EH; Durdle CA; Goodrich-Hunsaker NJ; Simon TJ; Bassett AS; Butcher NJ; Chow EWC; Vila-Rodriguez F; Cunningham A; Doherty J; Linden DE; Moss H; Owen MJ; van den Bree M; Crossley NA; Repetto GM; Thompson PM; Bearden CE Am J Psychiatry; 2020 Jul; 177(7):589-600. PubMed ID: 32046535 [TBL] [Abstract][Full Text] [Related]
18. Morphological brain changes associated with negative symptoms in patients with 22q11.2 Deletion Syndrome. Mihailov A; Padula MC; Scariati E; Schaer M; Schneider M; Eliez S Schizophr Res; 2017 Oct; 188():52-58. PubMed ID: 28139357 [TBL] [Abstract][Full Text] [Related]
19. Pituitary dysmaturation affects psychopathology and neurodevelopment in 22q11.2 Deletion Syndrome. Sandini C; Chambaz M; Schneider M; Armando M; Zöller D; Schaer M; Sandi C; Van De Ville D; Eliez S Psychoneuroendocrinology; 2020 Mar; 113():104540. PubMed ID: 31958652 [TBL] [Abstract][Full Text] [Related]
20. The interaction between neurocognitive functioning, subthreshold psychotic symptoms and pharmacotherapy in 22q11.2 deletion syndrome: A longitudinal comparative study. Weinberger R; Weisman O; Guri Y; Harel T; Weizman A; Gothelf D Eur Psychiatry; 2018 Feb; 48():20-26. PubMed ID: 29331595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]